Related by context. All words. (Click for frequent words.) 70 mCRC patients 70 recurrent glioblastoma multiforme 70 leukemia AML 70 metastatic GIST 70 HER2 positive metastatic breast 69 relapsed MM 69 stage IIIb IV 69 antibody MAb 69 ELACYT 69 CIMZIA TM certolizumab pegol 69 metastatic pancreatic 68 refractory chronic lymphocytic 68 leukemia CLL 68 metastatic colorectal 68 mRCC 68 pegylated liposomal doxorubicin 68 locoregional 68 metastatic malignant melanoma 68 galiximab 68 Leukemias 68 gemcitabine Gemzar 68 FOLFIRI 68 NMIBC 68 Hormone Refractory Prostate Cancer 67 FOLFOX6 67 lymphoid malignancies 67 metastatic malignant 67 gefitinib Iressa 67 Cloretazine 67 colorectal carcinoma 67 demonstrated antitumor activity 67 tumors GIST 67 Pemetrexed 67 azacytidine 67 Folfox 67 MAGE A3 ASCI 67 Doxil ® 67 erlotinib Tarceva ® 67 KRAS wild 67 HBeAg negative 67 metastatic castration resistant 67 mapatumumab 67 sorafenib Nexavar 67 unresectable stage 67 prostate carcinoma 67 Hodgkin lymphoma HL 66 locoregional recurrence 66 Metastatic Melanoma 66 CYT# potent vascular disrupting 66 irinotecan containing 66 alkylating agent 66 Aflibercept 66 dacarbazine DTIC 66 invasive aspergillosis 66 LHRH receptor positive 66 metastatic gastric 66 cetuximab Erbitux R 66 Xelox 66 metastatic renal cell carcinoma 66 Xanafide 66 alfa 2a 66 Pooled Analysis 66 FOLFIRI alone 66 Antitumor Activity 66 Pegylated Interferon 66 Bevacizumab 66 FOLFOX4 66 Philadelphia Chromosome Positive 66 ara C 66 Metastatic Colorectal Cancer 66 Adjuvant chemotherapy 66 cisplatin resistant 66 Glioblastoma Multiforme 66 carboplatin paclitaxel 66 HCV RESPOND 2 66 EGFR expressing mCRC 66 Squamous 66 myelodysplastic myeloproliferative diseases 66 Azacitidine 66 dasatinib Sprycel ® 66 comparator arm 66 Patients Receiving 66 Diffuse Large B 66 estramustine 66 ZACTIMA 66 Squamous Cell Carcinoma 66 nonmetastatic 66 pancreatic carcinoma 66 GISTs 66 metastatic castrate resistant 66 HCV SPRINT 66 bevacizumab Avastin ® 66 cilengitide 66 riociguat 66 Relapsed Refractory 66 hormone refractory metastatic prostate 65 receptor tyrosine kinase inhibitor 65 Phase 2b Clinical Trial 65 prostate cancer PCa 65 systemic anaplastic large 65 Genasense ® 65 keloid scarring 65 CD3 monoclonal antibody 65 thalidomide Thalomid 65 acute leukemias 65 Amrubicin 65 Temsirolimus 65 nodal metastasis 65 nonsmall cell lung cancer 65 complement inhibitor eculizumab 65 K ras mutations 65 cediranib 65 KRAS mutations 65 neurologic progression 65 Patients Treated With 65 anthracycline taxane 65 p# biomarker 65 basal cell carcinoma BCC 65 Pralatrexate 65 KRAS status 65 Voreloxin 65 Annamycin 65 hA# 65 prostate cancer CRPC 65 Peginterferon 65 papillary renal cell carcinoma 65 Fludarabine 65 Brentuximab Vedotin SGN 65 Neoadjuvant 65 5 fluorouracil leucovorin 65 cell lymphoma CTCL 65 Papillary 65 low dose cytarabine 65 Irinotecan 65 stage IIIB 65 Aplidin 65 Lenalidomide 65 deletion 5q 65 EGFR mutation positive 65 Vidaza ® 65 Randomized Phase 65 recurrent metastatic 65 indolent follicular non 65 essential thrombocythemia ET 65 underwent resection 65 cetuximab Erbitux 65 Vidaza azacitidine 65 AEG# 65 Crohn disease CD 65 PEGylated Fab fragment 65 Hurthle cell 65 metastatic RCC 65 Stage IIIb 65 Surgical resection 65 mCRC 65 EGFR TKI 65 5-fluorouracil/leucovorin 65 BR.# 65 gastrointestinal stromal tumor GIST 65 paclitaxel cisplatin 65 Follicular Lymphoma 65 invasive candidiasis 65 Renal Cell Carcinoma 65 thrombocytopenic 65 BEXXAR Therapeutic Regimen 65 selective modulator 65 pertuzumab 65 oblimersen 65 BRIM2 65 Cloretazine ® 65 distant metastasis 65 cisplatin gemcitabine 64 HIV HCV coinfected 64 Malignant Melanoma 64 sunitinib malate 64 IV NSCLC 64 lenalidomide Revlimid R 64 pediatric acute lymphoblastic 64 Trial Evaluating 64 Mantle Cell Lymphoma 64 recurrent NSCLC 64 pheochromocytoma 64 Cutaneous T 64 interferon gamma 1b 64 CLL SLL 64 leukemia ALL 64 MGd 64 orally administered inhibitor 64 5-FU/LV 64 Refractory Hodgkin Lymphoma 64 prospectively defined 64 Epratuzumab 64 myelofibrosis polycythemia vera 64 Fluorouracil 64 atypical hemolytic uremic syndrome 64 posaconazole 64 allogeneic HSCT 64 hypereosinophilic syndrome 64 type KRAS 64 Golimumab 64 gastric adenocarcinoma 64 Anthracycline 64 metachronous 64 Afatinib 64 mutated K ras 64 transplantation HCT 64 CIMZIA ™ 64 EGFR mutation 64 Bortezomib 64 K ras 64 metastatic kidney 64 biliary tract cancer 64 idarubicin 64 gemcitabine carboplatin 64 Enzastaurin 64 docetaxel Taxotere ® 64 paclitaxel Taxol 64 pancreatic prostate 64 Paraplatin ® carboplatin 64 Vicinium TM 64 Myelodysplastic Syndromes 64 docetaxel chemotherapy 64 Fulvestrant 64 Myelofibrosis 64 Pharmacokinetics PK 64 HGS ETR2 64 differentiated thyroid 64 relapsing remitting MS RRMS 64 liver metastasis 64 histological subtype 64 GOUT 64 Multiple Myeloma MM 64 XIENCE V PROMUS Stent 64 Soft Tissue Sarcoma 64 fallopian tube carcinoma 64 Chronic Lymphocytic Leukemia 64 heavily pretreated 64 histologies 64 neuroendocrine cancers 64 gastrointestinal stromal tumors GIST 64 squamous histology 64 SPRYCEL ® 64 Pivotal Phase III 64 prostate cancer HRPC 64 CALGB # [002] 64 metastatic renal 64 ABCB1 64 refractory metastatic 64 GW# [003] 64 myeloproliferative neoplasms 64 IFN α 64 Dapagliflozin 64 Ozarelix 64 imatinib Gleevec 64 ErbB2 positive 64 familial amyloidotic polyneuropathy FAP 64 refractory acute myeloid 64 glufosfamide 64 epithelial tumors 64 standard chemotherapy regimens 64 Meets Primary Endpoint 64 allogeneic hematopoietic stem cell 64 Myelodysplastic Syndrome MDS 64 T#I [002] 64 relapsed multiple myeloma 64 histologically confirmed 64 EGFR HER2 64 INCB# [003] 64 allogeneic transplantation 64 FluCAM arm 64 Long Term Efficacy 64 Paraplatin ® 64 ovarian carcinoma 64 Androgen Deprivation Therapy 64 thymoma 64 clinically localized prostate 64 BRAF V#E mutation 64 Estrogen Receptor 64 BRIM3 64 acute myeloid 64 relapsed leukemia 64 mycophenolate mofetil 64 PKC# 64 tumor lysis syndrome 64 pancreatic adenocarcinoma 63 adriamycin 63 EOquin TM 63 standard chemotherapy regimen 63 Chronic Myeloid Leukemia 63 Epidermal Growth Factor Receptor 63 recurrent glioblastoma 63 clodronate 63 recurrent GBM 63 idiopathic thrombocytopenic purpura ITP 63 sarcomatoid 63 essential thrombocythemia 63 plus dexamethasone 63 unresectable tumors 63 pT2 63 pan HDAC inhibitor 63 rFVIIa 63 follicular lymphoma FL 63 metastatic HRPC 63 imatinib Gleevec ® 63 untreated multiple myeloma 63 chemoradiation therapy 63 FOLOTYN ® 63 allogeneic stem cell 63 nab paclitaxel 63 Adjuvant Treatment 63 MEK Inhibitor 63 gemcitabine Gemzar ® 63 HBeAg positive 63 chronic eosinophilic leukemia 63 HGS ETR1 63 Invasive Breast Cancer 63 B Cell Lymphoma 63 pretransplant 63 metastatic bladder 63 castration resistant prostate cancer 63 superficial bladder cancer 63 metastatic neuroendocrine tumors 63 Dacogen decitabine 63 sunitinib Sutent 63 Metastatic 63 F FDG PET 63 biochemical relapse 63 anthracycline containing 63 investigational monoclonal antibody 63 assessing T DM1 63 fallopian tube cancers 63 PROSTVAC VF 63 crizotinib PF # 63 Free Survival PFS 63 relapsed refractory multiple myeloma 63 tiuxetan 63 autologous transplants 63 Hepatocellular Carcinoma HCC 63 Chronic Sinusitis 63 SSc 63 afatinib 63 Lupus Nephritis 63 malignant lymphoma 63 Lymphocytic 63 chronic myeloid 63 Idiopathic Pulmonary Fibrosis 63 Paclitaxel Carboplatin 63 phase IIb clinical 63 FUSILEV enhances 63 HuMax EGFr 63 sorafenib tablets 63 melphalan prednisone 63 dacarbazine 63 VELCADE melphalan 63 heavily pretreated patients 63 Advanced Melanoma 63 Peginterferon Alfa 2a 63 haematological malignancies 63 neoadjuvant therapy 63 Pivotal Phase 63 IL# PE#QQR 63 malignant neoplasm 63 Prolongs Survival 63 azacitidine 63 Interferon Beta 63 IgG1 monoclonal antibody 63 deep venous thromboses 63 EGFr expressing metastatic colorectal 63 Investigational Treatment 63 heparin induced thrombocytopenia 63 BRCA deficient 63 candidemia 63 hepatitis C HCV 63 Pegylated 63 monoclonal antibody conjugated 63 Advanced Renal Cell 63 mutated KRAS 63 sorafenib Nexavar ® 63 Progenitor Cells 63 histologic subtype 63 Randomized Study 63 haematologic 63 antithymocyte globulin 63 non squamous 63 catheter occlusion 63 plus prednisone 63 imatinib therapy 63 Hodgkin lymphoma NHL 63 SCCHN 63 Navelbine ® 63 malignant pleural mesothelioma 63 malignant neoplasms 63 neratinib 63 potentially hepatotoxic 63 evaluating tivozanib 63 completely resected 63 5 Fluorouracil 63 pulmonary metastasis 63 JAK2 V#F 63 bevacizumab Avastin 63 recurrent malignant glioma 63 TO AVOID PREGNANCY WHILE 63 T1c 63 decitabine 63 nonmelanoma skin cancers 63 mycosis fungoides 63 biochemical recurrence 63 plus DOXIL 63 Clolar ® 63 relapsed ovarian cancer 63 Bosutinib 63 temsirolimus 63 stage IIIb 63 lymphoma CTCL 63 operable breast cancer 63 Allogeneic 63 bone metastasis 63 novel VDA molecule 63 taxane chemotherapy 63 Flu Cy 63 AVOREN 63 ribavirin RBV 63 Endometrial 63 mutated KRAS gene 63 relapsed acute myelogenous 63 seminoma 63 unresectable 63 FOLFOX chemotherapy 63 Dacogen injection 63 lamivudine resistant 63 paclitaxel carboplatin 63 Improved Survival 63 malignant ascites 63 non squamous NSCLC 62 interferon alfa 62 liposomal amphotericin B 62 endometrial hyperplasia 62 ritonavir boosted 62 micafungin 62 Naive Patients 62 PREZISTA r 62 BCIRG 62 pegylated interferon alpha 62 Velcade bortezomib 62 Relapsing Remitting Multiple Sclerosis 62 trastuzumab Herceptin ® 62 trans retinoic acid 62 inhibitor RG# 62 Perifosine 62 HBeAg positive patients 62 urothelial carcinoma 62 postoperative chemotherapy 62 steroid refractory 62 Proxinium TM 62 5 FU leucovorin 62 Tamibarotene 62 vandetanib 62 bevacizumab Avastin R 62 tumor xenograft models 62 allogeneic bone marrow 62 TTF Therapy 62 Copegus ribavirin 62 CDK inhibitor 62 ovarian endometrial 62 Pegylated Liposomal Doxorubicin 62 sunitinib Sutent ® 62 Degarelix 62 smoldering myeloma 62 Is Well Tolerated 62 prognostic indicator 62 achieved CCyR 62 small lymphocytic lymphoma 62 Vandetanib 62 alkylating 62 pancreatic islet cell 62 acute GvHD 62 Tanespimycin 62 carcinoma HCC 62 ductal adenocarcinoma 62 ISTODAX ® 62 OXi# 62 colorectal liver metastases 62 Acute Myeloid Leukaemia AML 62 GnRH agonists 62 axitinib 62 lung metastasis 62 RECIST Response Evaluation Criteria 62 resectable pancreatic cancer 62 Dasatinib 62 Newly Diagnosed Multiple Myeloma 62 PEG interferon 62 metastatic androgen independent 62 GRN# 62 Lenocta 62 underwent surgical resection 62 preoperative chemotherapy 62 Combination REOLYSIN R 62 multiple myeloma MM 62 Prospective Randomized 62 EGFr 62 acute peripheral arterial 62 plus gemcitabine 62 Kit CD# positive 62 GSTP1 62 neutropenia dehydration dyspnea 62 forodesine 62 metastatic hormone refractory 62 gastrointestinal stromal tumors 62 abacavir Ziagen 62 alvespimycin 62 Bezielle 62 cetuximab Erbitux ® 62 Capecitabine 62 Factor Receptor 62 Subgroup analysis 62 Intravitreal 62 Decitabine 62 satraplatin Phase 62 efaproxiral 62 recurrent glioblastoma multiforme GBM 62 malignant lymphomas 62 TNF blocker therapy 62 TNF antagonist 62 rALLy 62 corticosteroid therapy 62 novel tubulin binding 62 Anti Tumor Activity 62 neoplastic 62 breast carcinoma 62 resected pancreatic cancer 62 refractory CTCL 62 RAV# 62 anti leukemic 62 alkylating agents 62 panobinostat 62 myeloproliferative disorders 62 Non Alcoholic Steatohepatitis 62 malignant pleural mesothelioma MPM 62 Ranolazine 62 stage IIIA 62 CR nPR 62 Malignant Glioma 62 ® lenalidomide 62 MPS IVA 62 Mitomycin C 62 vinca alkaloids 62 Virologic 62 node metastases 62 Parathyroid Hormone 62 Metastatic breast cancer 62 CTEPH 62 skeletal metastases 62 induced macular edema 62 TNF Tumor Necrosis Factor 62 Fludara 62 Omacetaxine 62 Atypical Hemolytic Uremic Syndrome 62 APPRAISE 62 depsipeptide 62 Investigational Agent 62 primary hypercholesterolemia 62 BRAF inhibitor 62 myeloproliferative 62 lenalidomide dexamethasone 62 ovarian lung 62 untreated metastatic pancreatic 62 Camptosar ® 62 androgen deprivation 62 Chronic Hepatitis C 62 fluoropyrimidine oxaliplatin 62 EGFR expressing metastatic colorectal 62 adalimumab Humira 62 lymphomas leukemias 62 virus HCV protease inhibitor 62 cintredekin besudotox 62 Monotherapy 62 chlorambucil 62 Sezary syndrome 62 Akt inhibitor 62 cytopenias 62 MyVax R 62 terlipressin 62 squamous 62 cinacalcet 62 Tyrosine Kinase Inhibitor 62 taxane resistant 62 imetelstat 62 Immunosuppression 62 hepatic metastases 62 invasive ductal 62 trabectedin 62 grade cervical intraepithelial 62 DAPT 62 nicardipine 62 HSCT 62 Hsp# Inhibitor 62 hepatocellular carcinomas 62 MGUS 62 pomalidomide 62 erythematosus SLE 62 invasive lobular 62 medically inoperable 62 elacytarabine 62 Hematologic 62 fluoropyrimidine 62 Zolinza 62 carcinoid 62 untreated CLL 62 pancreatic ovarian 62 chemoresistant 62 AVASTIN 62 XYOTAX TM 62 antibody MT# 62 irreversible inhibitor 62 Daclizumab 62 PXD# 62 dasatinib Sprycel 62 Aurora Kinase 62 relapsed refractory 62 FEMALES SHOULD BE ADVISED 62 epithelial ovarian 62 ribavirin therapy 62 PDGFRA 62 tumor histology 62 Nilotinib 62 oral ridaforolimus 62 pancreatic colon 62 prostate cancer CaP 62 pT3 62 refractory multiple myeloma 62 chemoembolization 62 pancreatic neuroendocrine tumors 62 pegylated interferon alfa 2a 62 minimally symptomatic 61 Platinol ® cisplatin 61 metastatic renal cell 61 Azedra 61 Cloretazine R 61 homozygous familial hypercholesterolemia 61 JAK Inhibitor 61 PDX pralatrexate 61 refractory NSCLC 61 R Saizen R 61 hepatorenal syndrome 61 anastrazole 61 radiotherapy RT 61 colorectal adenoma 61 squamous cell carcinoma SCC 61 EGFR expressing 61 EFAPROXYN 61 vinca alkaloid 61 dasatinib 61 Anaplastic 61 FLT3 61 Previously Treated 61 paraganglioma 61 imatinib resistant 61 Phase IIb Trial 61 mTOR inhibitor 61 Adjuvant Chemotherapy 61 Achieves Primary Endpoint 61 palifermin 61 mutant KRAS 61 HBeAg 61 peritumoral brain edema 61 transplantation HSCT 61 TACE 61 FOLFOX 61 seliciclib 61 Median progression 61 vidofludimus 61 endoscopic remission 61 aflibercept 61 CCyR 61 MALT lymphoma 61 NSCLC 61 CIMZIA TM 61 LymphoStat B belimumab 61 bladder carcinoma 61 colorectal neoplasms 61 myelofibrosis MF 61 coinfected patients 61 chronic lymphocytic leukemia CLL 61 IV metastatic melanoma 61 hormone receptor negative 61 androgen independent 61 Nexavar sorafenib 61 systemic ALCL 61 relapsed ALL 61 platelet inhibitor 61 Exelixis XL# 61 INSPIRE Trial Phase III 61 Albuferon TM 61 neoplasias 61 antiangiogenic therapy 61 advanced metastatic renal 61 anthracycline chemotherapy 61 huC# DM4 61 Chronic Lymphocytic Leukemia CLL 61 ACTEMRA TM 61 B CLL 61 iniparib 61 Gliadel Wafer 61 metastatic CRC 61 PNP inhibitor 61 Advaxis Phase 61 null responder 61 vWD 61 Vitaxin 61 MKC# MT 61 Non Alcoholic Fatty 61 calcineurin inhibitors 61 KRAS mutations occur 61 TAXUS Express Stent 61 Neulasta ® 61 TREANDA 61 generation purine nucleoside 61 XL# inhibits 61 CINTREDEKIN BESUDOTOX 61 Hazard Ratio 61 follicular lymphomas 61 Granulocyte Colony Stimulating Factor 61 pancreatic lung 61 V#F mutation 61 registrational trial 61 Ischemic 61 NSABP B 61 resistant hormone refractory 61 Platinol ® 61 genotypic resistance 61 contralateral breast 61 enzastaurin 61 CTAP# Capsules 61 Gleevec resistant 61 oral prodrug 61 Phase #b/#a clinical 61 oral Hycamtin 61 de novo kidney transplant 61 Oral Fingolimod 61 hypomethylating agents 61 Tumor Response 61 non mutated KRAS 61 HER2 overexpression 61 Controlled Trial 61 anthracyclines taxanes 61 Response Evaluation Criteria 61 situ CIS 61 Patency 61 Relapsed Refractory Multiple Myeloma 61 ON #.Na 61 pain palliation 61 symptomatic BPH 61 antimetabolite 61 atypical Hemolytic Uremic Syndrome 61 subependymal giant cell 61 ^ sup #m 61 Eculizumab 61 prednisone prednisolone 61 intravesical therapy 61 refractory metastatic colorectal cancer 61 castrate resistant prostate cancer 61 fosbretabulin 61 Neovascular Age Related Macular 61 chemotherapy cisplatin 61 orthotopic model 61 PCa 61 KRAS mutation 61 Relapsing Multiple Sclerosis 61 TTR amyloidosis 61 evaluating picoplatin 61 metastatic ovarian cancer 61 adenomatous 61 Severe Sepsis 61 fluvastatin 61 HCD# [002] 61 bladder ovarian 61 Bivalirudin 61 Hedgehog Pathway Inhibitor 61 ER CHOP 61 gastric carcinoma 61 peritoneal cancer 61 Tarceva TM 61 lintuzumab 61 mTOR inhibitors 61 cervical lymph nodes 61 pharmacokinetic interactions 61 R lenalidomide 61 castrate resistant 61 visceral metastases 61 mucinous 61 Study Evaluating 61 trial evaluating PRX# 61 PEG IFN 61 Seliciclib 61 trastuzumab Herceptin R 61 oral clodronate 61 irinotecan doxorubicin oxaliplatin paclitaxel 61 caspofungin 61 Demonstrates Efficacy 61 hepatic failure 61 postmenopausal osteoporotic women 61 non splenectomized 61 ongoing Phase 1b 61 substantially excreted 61 untreated chronic lymphocytic 61 Temodar ® 61 ORENCIA ® 61 carcinoma mCRC 61 DOXIL 61 Novel Oral 61 ZOLINZA 61 Panzem R NCD 61 Virulizin R 61 sodium glucose cotransporter 61 Bayer Nexavar 61 Oncolytic 61 liver metastases 61 leukemia multiple myeloma 61 occlusion PAO 61 boosted protease inhibitor 61 Phase 2b Study 61 oral diclofenac 61 syngeneic 61 QTc prolongation 61 acute humoral rejection 61 glioblastoma multiforme GBM 61 Thiarabine 61 multikinase inhibitor 61 Virulizin ® 61 docetaxel prednisone 61 doxorubicin HCl liposome injection 61 myelodysplastic syndrome MDS 61 GRNCM1 61 HRPC 61 adjuvant radiotherapy 61 lopinavir r arm 61 IIa Clinical Trial 61 leukemia APL 61 eosinophilic asthma 61 GRASPA ® 61 Acute Myelogenous Leukemia AML 61 ceftazidime 61 HDAC Inhibitor 61 mitoxantrone plus 61 intestinal metaplasia 61 Plus Ribavirin 61 Navelbine 61 immunomodulatory therapy 61 Sapacitabine 61 bleomycin 61 irinotecan chemotherapy 61 XELOX 61 Romidepsin 61 Thromboembolic 61 hepatocellular carcinoma HCC 61 LUX Lung 61 Median PFS 61 Hepatotoxicity 61 clinically evaluable 61 leiomyomas 61 seropositive patients 61 lymphoproliferative diseases 61 lapatinib Tykerb 61 nilotinib 61 e antigen HBeAg 61 untreated metastatic melanoma 61 T#I mutant 61 flutamide 61 carcinoid tumors 61 Taxotere chemotherapy 61 lobular carcinoma 61 Cell Lymphoma 61 Glioblastoma multiforme GBM 61 mcg albinterferon alfa 2b 61 Infected Patients 61 Safinamide 61 liver transplant recipients 61 Ribavirin causes 61 Bucindolol 61 Candida infection 61 pathophysiological effects 61 Actinic Keratosis 61 Torisel 61 resectable 61 Placebo Controlled Trial 61 Phase III Trial 61 Factor VIIa 61 Immunohistochemical staining 61 STRIDE PD 61 ertapenem 61 pegylated interferon alfa 2b 61 refractory Hodgkin 61 MYCN amplification 61 EGFR receptor 61 Hormone Receptor Positive 61 plus dacarbazine 61 Survival Benefit 61 hemodynamically significant 61 evaluable 61 metastatic colorectal cancer 61 prostate adenocarcinoma 61 Relapsed Multiple Myeloma 61 Radiofrequency Ablation RFA 61 TRANSFORMS 61 Nebulized 61 immunocompetent 61 TTR gene 61 erythropoietic 61 Statistically Significant 61 soluble tumor necrosis 61 nucleoside analogue 61 cutaneous T 61 Relapsed Refractory Aggressive 61 Alemtuzumab 61 demethylating agent 61 leukaemias 61 dacarbazine chemotherapy 61 olaparib 61 Tezampanel 61 ximelagatran 61 Improves Outcomes 61 cyclophosphamide methotrexate 61 Shows Statistically Significant 61 orthotopic 61 Cimzia TM 61 Complicated Skin 61 radiolabeled TM# 61 relapsing multiple sclerosis 61 antiproliferative effects 61 radioiodine therapy 61 chemosensitizer 61 LEP ETU 61 BRAF mutant 61 chemoradiotherapy 61 OncoVEX GM CSF 60 RG# [001] 60 Taxotere ® 60 benign prostatic hypertrophy BPH 60 canakinumab 60 LBH# 60 Everolimus 60 Actimmune ® 60 SUPPRELIN R LA 60 Ranibizumab 60 preterm newborns 60 refractory indolent non 60 gastrointestinal stromal tumor 60 grade glioma 60 TRAIL R1 60 Trastuzumab 60 velafermin 60 Eprodisate 60 cholangiocarcinoma 60 Gemzar ® 60 intra abdominal abscess 60 Palifosfamide 60 lymphocytosis 60 Renal Cell Carcinoma RCC 60 CC genotype 60 efavirenz EFV 60 debulking surgery 60 octreotide LAR 60 cMET 60 undetectable HBV DNA 60 EURIDIS 60 elotuzumab 60 vismodegib 60 Acute Myocardial Infarction 60 neoadjuvant 60 severe neutropenia 60 BARACLUDE ® 60 APTIVUS r 60 taxane therapy 60 Personalized Immunotherapy 60 hepatocellular cancer 60 YONDELIS 60 carcinoma HNSCC 60 5q deletion 60 Chronic lymphocytic leukemia 60 inducible nitric oxide synthase 60 treatment naive genotype 60 peginterferon alfa 60 Apaziquone 60 Elotuzumab 60 transthyretin TTR mediated amyloidosis 60 cranial irradiation 60 VP# [004] 60 relapsed mantle 60 fluorouracil leucovorin 60 TroVax ® 60 KRAS mutant 60 II Clinical Trial 60 posttransplant 60 adjunctive placebo 60 vincristine doxorubicin 60 myeloproliferative diseases 60 response CCyR 60 TLK# 60 HCV genotypes